Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 27

Using zebrafish to accelerate DIPG drug development

A critical barrier to improvements in diffuse intrinsic pontine glioma (DIPG) therapy is a lack of new drugs that have a broad therapeutic index. In DIPG, validation of new therapeutics is hampered by the long time (6 months) that most human DIPG tumors take to kill mice. This means that it ...

Advanced RNAi therapeutics for DIPG

Diffuse intrinsic pontine glioma (DIPG) is a form of brain tumor that arises in the brainstem of children and is nearly 100% fatal with a median survival of 9-12 months after diagnostic. The location of these highly infiltrating tumors in the ventral pons precludes surgical resection and clinical trials with different ...

Short-pulse ultrasound delivery of panobinostat for the treatment of diffuse ...

Children with diffuse intrinsic pontine gliomas (DIPGs) have a 2-year survival rate of less than 10%. Compared to other brain cancers, DIPG is particularly difficult to treat because it spreads behind an intact blood-brain barrier (BBB) affecting healthy developing paediatric brain tissue. There are currently no effective treatments for this disease. ...

Polyamine pathway metabolism as a novel therapeutic option for Diffuse ...

Diffuse intrinsic pontine glioma (DIPG) is the most aggressive of all childhood cancers. Standard treatment with radiotherapy is only palliative and chemotherapy has been found ineffective. Polyamines are organic compounds essential for key functions of living cells. They can be made by human cells but also generated from intestinal microorganisms ...

Investigating the role of DIPG-derived exosomes in tumor growth and ...

Diffuse Intrinsic Pontine Glioma (DIPG) is a highly aggressive and infiltrating brain tumor affecting children for which there is no effective treatment. Sequencing data have revealed  the existence of well defined subgroups of tumors based on age of onset, specific location in the brain, mutations and clinical outcome. Those ...